Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine-containing Treatment Shortening Regimens for Pulmonary TB
NCT02410772Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Jan 2016
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of rifapentine, moxifloxacin in pulmonary tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Started Jan 2016; status: completed.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02410772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410772.